Antiretroviral Activity of AMD11070 (An Orally Administered CXCR4 Entry Inhibitor): Results of NIH/NIAID AIDS Clinical Trials Group Protocol A5210

AMD11070 binds to the chemokine receptor CXCR4, with anti-HIV-1 activity in vitro and in vivo. We conducted a phase IB/IIA proof-of-concept dose-escalating, open-label study to determine safety and antiviral activity of AMD11070 administered over 10 days to HIV-1-infected participants who harbored C...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS Res Hum Retroviruses
Main Authors: Johnson, Victoria A., Cramer, Yoninah S., Rosenkranz, Susan L., Becker, Stephen, Klingman, Karin L., Kallungal, Beatrice, Coakley, Eoin, Acosta, Edward P., Calandra, Gary, Saag, Michael S.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2019
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6688111/
https://ncbi.nlm.nih.gov/pubmed/31099252
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2018.0256
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados